PMID- 38197267
OWN - NLM
STAT- MEDLINE
DCOM- 20240328
LR  - 20240404
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 20
IP  - 14
DP  - 2024 May
TI  - INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for 
      relapsed/refractory myeloma in routine practice.
PG  - 935-950
LID - 10.2217/fon-2023-0604 [doi]
AB  - Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and 
      REMIX) to investigate the real-world effectiveness of 
      ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. 
      Materials & methods: INSIGHT MM was a prospective study conducted in countries 
      across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were 
      multicenter, retrospective/prospective studies conducted in Europe. Patients who 
      had received IRd as >/=2nd line of therapy were analyzed. Primary outcomes were 
      time-to-next treatment (TTNT) and progression-free survival (PFS). Results: 
      Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT 
      and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for 
      earlier versus later lines. Median treatment duration was 14.0 months. Overall 
      response rate was 64.6%. No new safety concerns were noted. Conclusion: The 
      effectiveness of IRd in routine practice appears similar to the efficacy observed 
      in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with 
      previous reports.
FAU - Leleu, Xavier
AU  - Leleu X
AUID- ORCID: 0000-0002-9822-4170
AD  - Pole Regional de Cancerologie, Department of Hematology, CHU La 
      Miletrie-Poitiers, Poitiers, 86000, France.
FAU - Lee, Hans C
AU  - Lee HC
AD  - M.D. Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zonder, Jeffrey A
AU  - Zonder JA
AD  - Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, 
      Detroit, MI 48201, USA.
FAU - Macro, Margaret
AU  - Macro M
AD  - CHU de Caen, Caen, 14000, France.
FAU - Ramasamy, Karthik
AU  - Ramasamy K
AD  - Department of Haematology, Oxford University Hospitals NHS Foundation Trust, 
      Oxford, Oxfordshire, OX3 7LE, UK.
FAU - Hulin, Cyrille
AU  - Hulin C
AD  - CHU de Bordeaux, Bordeaux, 33000, France.
FAU - Silar, Jiri
AU  - Silar J
AD  - Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic.
FAU - Kuhn, Matyas
AU  - Kuhn M
AD  - Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic.
FAU - Ren, Kaili
AU  - Ren K
AD  - Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA.
FAU - Bent-Ennakhil, Nawal
AU  - Bent-Ennakhil N
AD  - Takeda Pharmaceuticals International AG, Opfikon, 8152, Switzerland.
FAU - Cherepanov, Dasha
AU  - Cherepanov D
AD  - Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA.
FAU - Stull, Dawn Marie
AU  - Stull DM
AD  - Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA.
FAU - Terpos, Evangelos
AU  - Terpos E
AD  - Department of Clinical Therapeutics, National & Kapodistrian University of 
      Athens, School of Medicine, Athens,115 27, Greece.
LA  - eng
GR  - Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20240110
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Boron Compounds)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - TE7660XO1C (Glycine)
RN  - 71050168A2 (ixazomib)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Humans
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Boron Compounds/therapeutic use
MH  - Dexamethasone/therapeutic use
MH  - *Glycine/analogs & derivatives
MH  - Lenalidomide/therapeutic use
MH  - Multicenter Studies as Topic
MH  - *Multiple Myeloma/drug therapy
MH  - Prospective Studies
MH  - Retrospective Studies
OTO - NOTNLM
OT  - IRd
OT  - effectiveness
OT  - ixazomib
OT  - ixazomib-lenalidomide-dexamethasone
OT  - multiple myeloma
OT  - pooled analysis
OT  - progression-free survival
OT  - proteasome inhibitor
OT  - relapsed/refractory
OT  - routine clinical practice
OT  - time-to-next treatment
EDAT- 2024/01/10 06:42
MHDA- 2024/03/28 06:46
CRDT- 2024/01/10 05:28
PHST- 2024/03/28 06:46 [medline]
PHST- 2024/01/10 06:42 [pubmed]
PHST- 2024/01/10 05:28 [entrez]
AID - 10.2217/fon-2023-0604 [doi]
PST - ppublish
SO  - Future Oncol. 2024 May;20(14):935-950. doi: 10.2217/fon-2023-0604. Epub 2024 Jan 
      10.